Biogen Concludes its Participation in LFA-1 Antagonist Drug Development Program

Biogen, Inc. (NASDAQ/ BGEN) today announced the conclusion of its collaboration with ICOS Corporation to develop LFA-1 (Leukocyte Function-associated Antigen-1) antagonists. IC747, an orally administered LFA-1 antagonist, was designed to interfere with T-cell activation and leukocyte trafficking by inhibiting the binding of LFA-1 to its ligand. Biogen and ICOS were studying IC747 as a possible oral therapeutic for the treatment of inflammatory conditions.

About Biogen
Biogen is the world’s oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients’ lives around the world through its global marketing capabilities. For press releases and additional information about the company, please visit

Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
(617) 914-6524

Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
(617) 679-2812